Sector: HealthcareIndustry: Biotechnology
Aardvark Therapeutics Inc
Current Price
Analyst Sentiment
7 ratings: Buy
Strong Buy
3
Buy
4
Hold
0
Sell
0
Strong Sell
0
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the development of innovative small-molecule therapies aimed at activating innate homeosta...|
Overview
Market Cap$201.62M
52W High / Low$20 / $5
P/EN/A
PEGN/A
Book Value$5.63
Dividend/ShareN/A
Dividend YieldN/A
EPS$-2.46
Revenue/ShareN/A
OPM0.00%
NPM0.00%
ROA-30.80%
ROE-48.10%
Gross Profit$0
Forward PEN/A
Price to SalesN/A
Price to Book1.78
EV to SalesN/A
EV to EBITDAN/A
BetaN/A
50D Moving Avg$12.04
200D Moving Avg$11.10
Institutional Holding53.17%
Insider Holding14.51%
Trailing P/EN/A
Qtr EPS GrowthN/A
Qtr Revenue GrowthN/A
Add ratio to table
e.g. Promoter holding
Loading price data...
Earnings Estimates
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2025 | FY 2026 |
|---|---|---|
EPS Estimate (avg) | $-2.94 | $-3.43 |
Revenue Estimate (avg) | 0 | 0 |
EPS Revision (30d avg) | +0.1% | +1.3% |
Peer Comparison
Showing 5 peers (Same Industry)
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Acumen Pharmaceuticals Inc | ABOS | $106.00M | — | 1.22 | — | — | -85.90% | — |
| 2. | Anixa Biosciences Inc | ANIX | $138.25M | — | 8.73 | — | — | -62.20% | — |
| 3. | Protara Therapeutics Inc | TARA | $240.01M | — | 2.15 | — | — | -49.40% | — |
| 4. | Eledon Pharmaceuticals Inc | ELDN | $111.05M | — | 3.25 | — | — | -95.50% | — |
| 5. | Forte Biosciences Inc | FBRX | $172.07M | — | 2.77 | — | — | -73.50% | — |
Quarterly Results
Consolidated Figures in Millions / View Standalone.
View:
| Quarter (M) | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 |
|---|---|---|---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Expenses | 2.21 | 2.17 | 6.07 | 5.09 | 9.45 | 10.47 | 15.85 | 17.69 |
Operating Profit | -2.04 | -2.17 | -6.07 | -5.09 | -9.45 | -10.47 | -15.85 | -16.32 |
OPM % | - | - | - | - | - | - | - | - |
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 0.03 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
Profit Before Tax | -2.04 | -2.18 | -5.45 | -4.18 | -8.78 | -9.31 | -14.37 | -16.32 |
Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Profit | -2.04 | -2.18 | -5.45 | -4.18 | -8.78 | -9.31 | -14.37 | -16.32 |
EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit & Loss
Consolidated Figures in Millions / View Standalone.
View:
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|
Sales | 0 | 0 | 0 |
COGS | 0.11 | 0.1 | 0.02 |
Gross Profit | -0.11 | -0.1 | -0.02 |
Gross Profit % | - | - | - |
Operating Exp | 11.36 | 7.42 | 22.79 |
EBITDA | -9.76 | -6.65 | -22.65 |
Other Income | 0 | 0 | 0 |
Interest | 0.12 | 1.42 | 2.41 |
Depreciation | 0.11 | 0.76 | 0.02 |
Profit Before Tax | -13.56 | -7.21 | -20.59 |
Tax Rate % | 0% | 0% | 0% |
Net Profit | -13.56 | -7.21 | -20.59 |
Balance Sheet
Consolidated Figures in Millions / View Standalone.
View:
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|
Cash & Bank | 15.56 | 9.73 | 61.64 |
Investments | 0.55 | 0.25 | 12.02 |
Fixed Assets | 0 | 0 | 0 |
Current Assets | 0.39 | 0.38 | 0.47 |
Other Assets | 0.27 | 0.17 | 3.37 |
Total Assets | 16.76 | 10.54 | 77.51 |
Equity Capital | 0 | 0 | 0 |
Reserves | -27.92 | -34.8 | -54.64 |
Borrowing/Debt | 0.26 | 0.16 | 0.78 |
Current Liabilities | 0.49 | 1.27 | 4.59 |
Other Liabilities | 43.92 | 43.91 | 126.78 |
Total Liabilities & Equity | 16.76 | 10.54 | 77.51 |
Cash Flow Statement
Consolidated Figures in Millions / View Standalone.
View:
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|
Cash Flow from Operating | -10.54 | -5.82 | -18.09 |
Cash Flow from Investing | -1 | 0 | -12 |
Cash Flow from Financing | 0.23 | 0 | 81.99 |
Net Cash Flow | 0 | 0 | 0 |